Comparative aneugenicity of doxorubicin and its derivative idarubicin using fluorescence in situ hybridization techniques

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 715, Issue 1-2, 2011, Pages 79-87

  Attia, Sabry M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Aneuploidy; Anthracyclines; Fluorescence in situ hybridization (FISH); Meiotic delay; Micronuclei (MN)

Indexed keywords

COLCHICINE; DOXORUBICIN; IDARUBICIN; MITOMYCIN C;

ANEUPLOIDY; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE ARREST; CENTROMERE; CHROMOSOME LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIPLOIDY; DISOMY; DNA STRAND BREAKAGE; FLUORESCENCE IN SITU HYBRIDIZATION; MALE; MEIOSIS; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHASE; SPERM;

ANEUGENS; ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; BROMODEOXYURIDINE; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; IDARUBICIN; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICRONUCLEUS TESTS; PEPTIDES;

MUS;

EID: 80052621949     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.07.012     Document Type: Article

References (45)

1. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54:1-7.
2. Ames M.M., Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992, 6:70-75.
3. Willmore E., Errington F., Tilby M.J., Austin C.A. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem. Pharmacol. 2002, 63:1807-1815.
4. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
5. Olsen A.K., Lindeman B., Wiger R., Duale N., Brunborg G. How do male germ cells handle DNA damage?. Toxicol. Appl. Pharmacol. 2005, 207:521-531.
6. Gamen S., Anel A., Perez-Galan P., Lasierra P., Johnson D., Pineiro A., Naval J. Doxorubicin treatment activates a ZVAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp. Cell Res. 2000, 258:223-235.
7. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 2001, 4:303-313.
8. F. Mitelman, B. Johansson, F. Mertens, 2010. Mitelman Database of Chromosome Aberrations in Cancer, http://cgap.nci.nih.gov/Chromosomes/Mitelman.
9. Fritz B., Aslan M., Kalscheuer V., Ramsing M., Saar K., Fuchs B., Rehder H. Low incidence of UPD in spontaneous abortions beyond the 5th gestational week. Eur. J. Hum. Genet. 2001, 9:910-916.
10. Robbins W.A., Meistrich M.L., Moor D., Hagemeister F.B., Weier H.-U., Cassel M.J., Wilson G., Eskenazi B., Wyrobek A.J. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat. Genet. 1997, 16:74-78.
11. Spriggs E.L., Rademaker A.W., Martin R.H. Aneuploidy in human sperm: the use of multicolour FISH to test various theories of nondisjunction. Am. J. Hum. Genet. 1996, 58:356-362.
12. Schmid T.E., Xu W., Adler I.D. Detection of aneuploidy by multicolor FISH in mouse sperm after in vivo treatment with acrylamide, colchicine, diazepam or thiabendazole. Mutagenesis 1999, 14:173-179.
13. Baumgartner A., Schmid T.E., Schuetz C.G., Adler I.D. Detection of aneuploidy in rodent and human sperm by multicolor FISH after chronic exposure to diazepam. Mutat. Res. 2001, 490:11-19.
14. Bonassi S., Znaor A., Ceppi M., Lando C., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Cebulska-Wasilewska A., Fabianova E., Fucic A., Hagmar L., Joksic G., Martelli A., Migliore L., Mirkova E., Scarfi M.R., Zijno A., Norppa H., Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 2007, 28:625-631.
15. Schmid T.E., Attia S., Baumgartner A., Nuesse M., Adler I.D. Effect of chemicals on the duration of male meiosis in mice detected with laser scanning cytometry. Mutagenesis 2001, 16:339-343.
16. Attia S.M., Schmid T.E., Badary O.A., Hamada F.M., Adler I.D. Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutat. Res. 2002, 520:1-13.
17. Attia S.M. Use of centromeric and telomeric DNA probes in in situ hybridization for differentiation of micronuclei induced by lomefloxacin. Environ. Mol. Mutagen. 2009, 50:394-403.
18. Attia S.M. The genotoxic and cytotoxic effects of nicotine in the mouse bone marrow. Mutat. Res. 2007, 632:29-36.
19. Schriever-Schwemmer G., Adler I.D. Differentiation of micronuclei in mouse bone marrow cells: a comparison between CREST staining and fluorescent in situ hybridization with centromeric and telomeric DNA probes. Mutagenesis 1994, 9:333-340.
20. Attia S.M., Kliesch U., Schriever-Schwemmer G., Badary O.A., Hamada F.M., Adler I.D. Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ. Mol. Mutagen. 2003, 41:99-103.
21. Attia S.M. Chromosomal composition of micronuclei in mouse bone marrow treated with rifambicin and nicotine, analyzed by multicolor fluorescence in situ hybridization with pancentromeric DNA probe. Toxicology 2007, 235:112-118.
22. Oakberg E.F. Duration of spermatogenesis in the mouse and timing of stages of the cycle of the seminiferous epithelium. Am. J. Anat. 1956, 99:507-516.
23. Martin R.H., McInnes B., Rademaker A.W. Analysis of aneuploidy for chromosomes 13, 21, X and Y by multicolour fluorescence in situ hybridisation (FISH) in a 47,XYY male. Zygote 1999, 7:131-134.
24. Attia S.M. Mutagenicity of some topoisomerase II-interactive agents. S.P.J. 2008, 17:1-24.
25. Attia S.M., Badary O.A., Hamada F.M., de Angelis M.H., Adler I.D. Orthovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythrocytes at the same dose level. Mutat. Res. 2005, 583:158-167.
26. Pacchierotti F., Ranaldi R., Eichenlaub-Ritter U., Attia S., Adler I.D. Evaluation of aneugenic effects of bisphenol A in somatic and germ cells of the mouse. Mutat. Res. 2008, 651:64-70.
27. Adler I.D. Synopsis of the in vivo results obtained with the 10 known or suspected aneugens tested in the CEC collaborative study. Mutat. Res. 1993, 287:131-137.
28. Miller B.M., Adler I.D. Aneuploidy induction in mouse spermatocytes. Mutagenesis 1992, 7:69-76.
29. Ling Y.H., el-Naggar A.K., Priebe W., Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol. 1996, 49:832-841.
30. Pytel D., Wysocki T., Majsterek I. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2006, 144:85-92.
31. Murray A.W. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992, 359:599-604.
32. Aly M.S., Othman O.E., El Nahas S.M. Specific numerical chromosomal aberrations induced by adriamycin. Environ. Mol. Mutagen. 1999, 33:161-166.
33. Ganapathi R., Hoeltge G., Casey G., Grabowski D., Neelon R., Ford J. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies. Cancer Genet. Cytogenet. 1996, 86:116-119.
34. Venizelos I.D., Klonizakis I., Vlahaki E., Haralambidou S., Tatsiou Z., Ioannidou E. Skin relapse of acute myeloid leukemia associated with trisomy 8. Acta Dermatovenerol. Alp. Panonica Adriat. 2007, 16:77-80.
35. Islam M.Q., Kopf I., Levan A., Granberg S., Friberg L.G., Levan G. Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. Cancer Genet. Cytogenet. 1993, 65:35-46.
36. Pedersen-Bjergaard J., Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases. Br. J. Haematol. 1987, 66:199-207.
37. Adler I.D., Schmid T.E., Baumgartner A. Induction of aneuploidy in male mouse germ cells detected by the sperm-FISH assay: a review of the present data base. Mutat. Res. 2002, 504:173-182.
38. Attia S.M., Badary O.A., Hamada F.M., de Angelis M.H., Adler I.D. The chemotherapeutic agents nocodazole and amsacrine cause meiotic delay and non-disjunction in spermatocytes of mice. Mutat. Res. 2008, 651:105-113.
39. Attia S.M., Bakheet S.A., Al-Rasheed N.M. Proanthocyanidins produce significant attenuation of doxorubicin-induced mutagenicity via suppression of oxidative stress. Oxid. Med. Cell Longev. 2010, 3:404-413.
40. de Campos Nebel M., Larripa I., González-Cid M. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice. Environ. Mol. Mutagen. 2002, 39:3-9.
41. Dhawan A., Kayani M.A., Parry J.M., Parry E., Anderson D. Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis 2003, 18:487-490.
42. Attia S.M., Aleisa A.M., Bakheet S.A., Al-Yahya A.A., Al-Rejaie S.S., Ashour A.E., Al-Shabanah O.A. Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan and irinotecan. Environ. Mol. Mutagen. 2009, 50:145-151.
43. Cortés F., Pastor N., Mateos S., Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat. Res. 2003, 543:59-66.
44. Holm C., Stearns T., Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol. Cell Biol. 1989, 9:159-168.
45. Alberts B., Bray D., Lewis J., Raff M., Roberts K., Watson J.D. Molecular Biology of the Cell 1994, Garland Publishing, New York. third ed.